Interleukin-22 Contributes to Blood–Brain Barrier Disruption via STAT3/VEGFA Activation in Escherichia coli Meningitis

Ruicheng Yang,Jiaqi Chen,Xinyi Qu,Hulin Liu,Xinyi Wang,Chen Tan,Huanchun Chen,Xiangru Wang
DOI: https://doi.org/10.1021/acsinfecdis.3c00668
IF: 5.578
2024-02-06
ACS Infectious Diseases
Abstract:<i>Escherichia coli</i> continues to be the predominant Gram-negative pathogen causing neonatal meningitis worldwide. Inflammatory mediators have been implicated in the pathogenesis of meningitis and are key therapeutic targets. The role of interleukin-22 (IL-22) in various diseases is diverse, with both protective and pathogenic effects. However, little is understood about the mechanisms underlying the damaging effects of IL-22 on the blood-brain barrier (BBB) in <i>E. coli</i> meningitis. We observed that meningitic <i>E. coli</i> infection induced IL-22 expression in the serum and brain of mice. The tight junction proteins (TJPs) components ZO-1, Occludin, and Claudin-5 were degraded in the mouse brain and human brain microvascular endothelial cells (hBMEC) following IL-22 administration. Moreover, the meningitic <i>E. coli</i>-caused increase in BBB permeability in wild-type mice was restored by knocking out IL-22. Mechanistically, IL-22 activated the STAT3-VEGFA signaling cascade in <i>E. coli</i> meningitis, thus eliciting the degradation of TJPs to induce BBB disruption. Our data indicated that IL-22 is an essential host accomplice during <i>E. coli</i>-caused BBB disruption and could be targeted for the therapy of bacterial meningitis.
chemistry, medicinal,infectious diseases
What problem does this paper attempt to address?